NCT07661108
A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 7 words
- Trial completed
- Primary and study completion dates changed from estimate of Oct 9, 2026 to Oct 28, 2026
- Secondary endpoints: details revised at 9 of 22 entries
- Minor Enrollment closed, study ongoing
- Site details revised
- Notable Recruitment opened
- Study sites: 0 to 1
- Start date changed from estimate of Jul 7, 2026 to Jun 30, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Part 1: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma With and Without Food
Timeframe: Predose and at designated timepoints (up to 336 hours postdose)
Part 2: AUC0-inf of MK-8527 in Plasma With and Without Probenecid
Timeframe: Predose and at designated timepoints (up to 336 hours postdose)
Part 3: AUC0-inf of MK-8527 in Plasma With and Without Itraconazole
Timeframe: Predose and at designated timepoints (up to 336 hours postdose)
Secondary (22)
Part 1: Area Under the Concentration Time Curve From Time 0 to 336 Hours (AUC0-336) of MK-8527 in Plasma With and Without Food
Part 1: Time to Maximum Plasma Concentration (Tmax) of MK-8527 in Plasma With and Without Food
Part 1: Maximum Plasma Concentration (Cmax) of MK-8527 in Plasma With and Without Food
Part 1: Apparent Terminal Half-life (t1/2) of MK-8527 in Plasma With and Without Food
Part 1: Number of Participants Who Experience an Adverse Event (AE)
Show 17 moreShow less
Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE
Part 2: AUC0-336 of MK-8527 in Plasma With and Without Probenecid
Part 2: Tmax of MK-8527 in Plasma with and without Probenecid
Part 2: Cmax of MK-8527 in Plasma With and Without Probenecid
Part 2: Apparent Terminal t1/2 of MK-8527 in Plasma With and Without Probenecid
Part 2: Urine Concentration at 72 Hours of MK-8527
Part 2: Renal Clearance of MK-8527
Part 2: Number of Participants Who Experience an AE
Part 2: Number of Participants Who Discontinue Study Treatment Due to an AE
Part 3: AUC0-336 of MK-8527 in Plasma With and Without Itraconazole
Part 3: Tmax of MK-8527 in Plasma With and Without Itraconazole
Part 3: Cmax of MK-8527 in Plasma With and Without Itraconazole
Part 3: Apparent Terminal t1/2 of MK-8527 in Plasma With and Without Itraconazole
Part 3: Urine Concentration at 72 Hours of MK-8527
Part 3: Renal Clearance of MK-8527
Part 3: Number of Participants Who Experience an AE
Part 3: Number of Participants Who Discontinue Study Treatment Due to an AE
Arms and interventions
Part 1: MK-8527Experimental
Participants will receive a single dose of MK-8527 with food and a single dose of MK-8527 without food.
Part 2: MK-8527 + ProbenecidExperimental
Participants will receive a single dose of MK-8527 alone and a single dose of MK-8527 in combination with probenecid.
Part 3: MK-8527 + ItraconazoleExperimental
Participants will receive a single dose of MK-8527 alone and a single dose of MK-8527 in combination with itraconazole.
Drugs: MK-8527, Probenecid, Itraconazole
Sites
1 site in 1 country
- Fortrea Clinical Research Unit Inc ( Site 0001)Daytona Beach, Florida, United States